References
Original articles
Hadoux, J. et al. Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2309719 (2023)
Zhou, X. et al. First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2309457 (2023)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Romero, D. Activity of selpercatinib confirmed in phase III trials. Nat Rev Clin Oncol 21, 5 (2024). https://doi.org/10.1038/s41571-023-00837-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-023-00837-z
- Springer Nature Limited